406
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder

, ORCID Icon, , &
Pages 475-482 | Received 10 Dec 2017, Accepted 28 Mar 2018, Published online: 06 Apr 2018

References

  • World Health Organization. Depression. 2017 [cited 2017 Jun 21]. Available from: http://www.who.int/mediacentre/factsheets/fs369/en/
  • Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009 Aug;66(8):848–856. PubMed PMID: 19652124.
  • Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adher. 2012;6:369–388. PubMed PMID: 22654508; PubMed Central PMCID: PMC3363299.
  • Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol. 2017 May;152:21–37. PubMed PMID: 26724279; PubMed Central PMCID: PMC4919246.
  • Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27(3):49–65. PubMed PMID: 18956529.
  • Scherrer JF, Svrakic DM, Freedland KE, et al. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med. 2014 Mar;29(3):491–499. PubMed PMID: 24165926; PubMed Central PMCID: PMC3930792.
  • Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci. 2001 Jan;26(1):21–29. PubMed PMID: 11212590; PubMed Central PMCID: PMC1408038.
  • Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci. 2001 Jan;26(1):30–36. PubMed PMID: 11212591; PubMed Central PMCID: PMC1408040.
  • Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects – a possible opioid involvement in severe depression? J Mol Neurosci. 2002 Feb-Apr;18(1–2):143–149. PubMed PMID: 11931344.
  • Jordan MR, Morrisonponce D. Naloxone. Treasure Island, FL: StatPearls; 2017.
  • Turncliff R, DiPetrillo L, Silverman B, et al. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. Clin Ther. 2015 Feb 1;37(2):338–348. PubMed PMID: 25456560.
  • Harrison C. Trial watch: opioid receptor blocker shows promise in Phase II depression trial. Nat Rev Drug Discov. 2013 Jun;12(6):415. . PubMed PMID: 23722336.
  • McIntyre RS, Suppes T, Tandon R, et al. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry. 2017 Jun;78(6):703–713. PubMed PMID: 28682531.
  • Liu B, Zhang YL, et al. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. BMC Psychiatry. 2014 Nov 30;14:342. PubMed PMID: 25433539; PubMed Central PMCID: PMC4264336.
  • Serafini G, Howland RH, Rovedi F, et al. The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol. 2014 Sep;12(5):444–461. PubMed PMID: 25426012; PubMed Central PMCID: PMC4243034.
  • Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13: 23–29. PubMed PMID: 9402916.
  • Lalanne L, Ayranci G, Kieffer BL, et al. The kappa opioid receptor: from addiction to depression, and back. Front Psychiatry. 2014;5:170. PubMed PMID: 25538632; PubMed Central PMCID: PMC4258993.
  • Khroyan TV, Wu J, Polgar WE, et al. BU08073 a buprenorphine analogue with partial agonist activity at mu-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol. 2015 Jan;172(2):668–680. PubMed PMID: 24903063; PubMed Central PMCID: PMC4292977.
  • Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985 Feb;57(2):192–196. PubMed PMID: 2982388.
  • Wentland MP, Lou R, Lu Q, et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289–2294. PubMed PMID: 19282177; PubMed Central PMCID: PMC2791460.
  • Wentland MP, Lu Q, Lou R, et al. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2107–2110. PubMed PMID: 15808478.
  • Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661–680. PubMed PMID: 15966752.
  • Kuhlman JJ Jr., Lalani S, Magluilo J Jr., et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996 Oct;20(6):369–378. PubMed PMID: 8889672.
  • Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015 May;40(6):1448–1455. PubMed PMID: 25518754; PubMed Central PMCID: PMC4397403.
  • Picard N, Cresteil T, Djebli N, et al. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689–695. PubMed PMID: 15743975.
  • Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984 Sep–Oct;12(5):577–581. PubMed PMID: 6149907.
  • Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett. 2009 Apr;3(2):101–107. PubMed PMID: 19601871.
  • Fava M, Memisoglu A, Thase ME, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016 May 1;173(5):499–508. PubMed PMID: 26869247.
  • Alkermes, editor ALKS 5461: FORWARD-3 and FORWARD-4. In: American society of clinical psychopharmacology annual meeting.  Scottsdale, Arizona. 2016.
  • Alkermes, editor ALKS 5461 in major depressive disorder (MDD). In: Investor conference call at society of biological psychiatry annual meeting. San Diego, California. 2017.
  • Ho RC, Ho EC, Mak A. Cutaneous complications among i.v. buprenorphine users. J Dermatol. 2009 Jan;36(1):22–29. . PubMed PMID: 19207433.
  • Ho RC, Ho EC, Tan CH, et al. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse. 2009;35(3):199–202. PubMed PMID: 19462305.
  • Ho RCM, Chen KY, Broekman B, et al. Buprenorphine prescription, misuse and service provision: a global perspective. Adv Psychiatr Treat. 2009;15(5):354–363.
  • Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003 Apr–Jun;35(2):253–259. . PubMed PMID: 12924748.
  • Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015 Apr;76(4):e487–e498. PubMed PMID: 25919841.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.